Education
About Us
Working with TipRanks
Follow Us
Prothena (DE:0PT)
FRANKFURT:0PT
0PT Stock Chart & Stats
€7.85
€0.00(0.00%)
At close: 4:00 PM EST
€7.85
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.86 - €12.90
Previous CloseN/A
Volume0.00
Average Volume (3M)27.00
Market Cap
€433.06M
Enterprise Value€202.13M
Total Cash (Recent Filing)€307.53M
Total Debt (Recent Filing)€13.86M
Price to Earnings (P/E)―
Beta0.04
Next Earnings
May 13, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding53,832,980
10 Day Avg. Volume81
30 Day Avg. Volume27
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.83
Price to Sales (P/S)53.08
P/FCF Ratio-3.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.14Price Target Upside131.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.82
Revenue Forecast (FY)€96.13M
Bulls Say, Bears Say
Bulls Say
Milestone PaymentA substantial clinical milestone payment from a major partner tied to enrollment progress in a late-stage trial provides non-dilutive capital and signals partner confidence in the science.
Novel Therapeutic MechanismCoramitug's amyloid-depleting mechanism is different from stabilizers and could benefit patients with higher disease burden who respond poorly to current treatments.
Partnership-driven De-riskingMultiple large pharmaceutical partners advancing company-originated assets into fully funded late-stage trials materially de-risks the platform model and validates discovery capabilities while preserving development optionality.
Bears Say
Clinical Validation RiskTranslation risk persists as the platform moves toward clinical validation, and failure to reproduce preclinical effects in human trials could undermine future program value.
Intellectual PropertyQuestions about the strength of the platform-specific patent estate expose the company to competitive risk and potential legal challenges as programs progress toward clinical stages.
Platform ApplicabilityUncertainty about whether the platform can be applied to other intracellular proteinopathies raises questions about the long-term scalability and market opportunity for the technology.
Prothena News
0PT FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was €3.86 and its highest was €12.90 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is €433.06M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is May 13, 2026 which is in 58 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on Feb 19, 2026. The company reported -€0.349 earnings per share for the quarter, beating the consensus estimate of -€0.487 by €0.139.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -0.3.
How many shares outstanding does Prothena have?
Prothena has 53,832,980 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of -€0.349 in its last earnings report, beating expectations of -€0.487. Following the earnings report the stock price went down -1.974%.
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in DE:0PT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prothena Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€18.14 (131.06% Upside)
€18.14 (131.06% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.42%
12-Months-Change
Fundamentals
Return on Equity
-67.63%
Trailing 12-Months
Asset Growth
-40.76%
Trailing 12-Months
Company Description
Prothena
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
0PT Company Deck
0PT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful scientific and business progress — two partner programs advanced to Phase III, strong Phase II biomarker signals (40% reduction in a PD motor endpoint subset; 48% NT‑proBNP reduction for coramitug), introduction of a novel CYTOPE technology with encouraging preclinical TDP‑43 results, and a solid year‑end cash position ($308.4M). Material near‑term upside exists (up to $105M in 2026 milestones and ~ $3B in potential future milestones across partners). Offsetting risks include ARIA‑E safety concerns for PRX012 prompting re‑engineering, some non‑statistically significant secondary endpoints (6‑minute walk test), multi‑year timelines to Phase III primary completions (2029), continued net losses and burn, and reliance on partner decisions for key programs (PRX019). Overall, positives — pipeline advancement, strong partner validation, and a healthy cash balance — outweigh the operational and timing risks.View all DE:0PT earnings summaries0PT Stock 12 Month Forecast
Average Price Target
€18.14
▲(131.06% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
XOMA Royalty Corporation
―
Zevra Therapeutics
―
Corvus Pharmaceuticals
―
Alumis Inc.
―
Options Prices
Currently, No data available
---